William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.
Separately, UBS Group assumed coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They set a “buy” rating and a $21.00 price target on the stock.
Read Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 11/18 – 11/22
- 3 REITs to Buy and Hold for the Long Term
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
